{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:54:10Z","timestamp":1794808450356,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt GmbH, Neuherber, Germany"},{"name":"Helmholtz Zentrum M\u00fcnchen - Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt GmbH, Neuherberg, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overcoming the global health threat of HIV infection requires continuous pipelines of novel drug candidates. We identified the \u03b3-pyrone polyketides Aureothin\/Neoaureothin as potent hits by anti-HIV screening of an extensive natural compound collection. Total synthesis of a structurally diverse group of Aureothin-derivatives successfully identified a lead compound (<jats:bold>#7<\/jats:bold>) superior to Aureothin that combines strong anti-HIV activity (IC<jats:sub>90<\/jats:sub>&lt;45\u2009nM), photostability and improved cell safety. Compound <jats:bold>#7<\/jats:bold> inhibited <jats:italic>de novo<\/jats:italic> virus production from integrated proviruses by blocking the accumulation of HIV RNAs that encode the structural components of virions and include viral genomic RNAs. Thus, the mode-of-action displayed by compound <jats:bold>#7<\/jats:bold> is different from those of all current clinical drugs. Proteomic analysis indicated that compound <jats:bold>#7<\/jats:bold> does not affect global protein expression in primary blood cells and may modulate cellular pathways linked to HIV infection. Compound <jats:bold>#7<\/jats:bold> inhibited multiple HIV genotypes, including HIV-type 1 and 2 and synergistically inhibited HIV in combination with clinical reverse transcriptase and integrase inhibitors. We conclude that compound <jats:bold>#7<\/jats:bold> represents a promising new class of HIV inhibitors that will facilitate the identification of new virus-host interactions exploitable for antiviral attack and holds promise for further drug development.<\/jats:p>","DOI":"10.1038\/s41598-020-57843-9","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T11:03:18Z","timestamp":1580209398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2749-9003","authenticated-orcid":false,"given":"Alexander","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Roesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-6827","authenticated-orcid":false,"given":"Stefanie M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brack-Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"57843_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","volume":"392","author":"J Ghosn","year":"2018","unstructured":"Ghosn, J., Taiwo, B., Seedat, S., Autran, B. & Katlama, C. Hiv. Lancet 392, 685\u2013697, https:\/\/doi.org\/10.1016\/S0140-6736(18)31311-4 (2018).","journal-title":"Lancet"},{"key":"57843_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493\u2013505, https:\/\/doi.org\/10.1056\/NEJMoa1105243 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"10189","key":"57843_CR3","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"Alison J Rodger","year":"2019","unstructured":"Rodger, A. J. et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. The Lancet, https:\/\/doi.org\/10.1016\/S0140-6736(19)30418-0 (2019).","journal-title":"The Lancet"},{"key":"57843_CR4","unstructured":"WHO. HIV Drug Resistance Report 2017. Geneva, World Health Organization; Licence: CC BY-NC-SA 3.0 IGO (2017)."},{"key":"57843_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/np200906s","volume":"75","author":"DJ Newman","year":"2012","unstructured":"Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311\u2013335, https:\/\/doi.org\/10.1021\/np200906s (2012).","journal-title":"J. Nat. Prod."},{"key":"57843_CR6","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1128\/AAC.00515-10","volume":"54","author":"S Kremb","year":"2010","unstructured":"Kremb, S. et al. EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob. Agents Chemother. 54, 5257\u20135268, https:\/\/doi.org\/10.1128\/AAC.00515-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"57843_CR7","doi-asserted-by":"publisher","first-page":"e87487","DOI":"10.1371\/journal.pone.0087487","volume":"9","author":"M Helfer","year":"2014","unstructured":"Helfer, M. et al. The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor. PLoS One 9, e87487, https:\/\/doi.org\/10.1371\/journal.pone.0087487 (2014).","journal-title":"PLoS One"},{"key":"57843_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep20394","volume":"6","author":"S Rebensburg","year":"2016","unstructured":"Rebensburg, S. et al. Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Sci. Rep. 6, 20394, https:\/\/doi.org\/10.1038\/srep20394 (2016).","journal-title":"Sci. Rep."},{"key":"57843_CR9","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/AAC.00277-07","volume":"51","author":"H Nakata","year":"2007","unstructured":"Nakata, H. et al. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine. Antimicrob. Agents Chemother. 51, 2701\u20132708, https:\/\/doi.org\/10.1128\/AAC.00277-07 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"57843_CR10","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1128\/AAC.49.11.4465-4473.2005","volume":"49","author":"RJ Hazen","year":"2005","unstructured":"Hazen, R. J. et al. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob. Agents Chemother. 49, 4465\u20134473, https:\/\/doi.org\/10.1128\/AAC.49.11.4465-4473.2005 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"57843_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/mol.111.073189","volume":"80","author":"S Hare","year":"2011","unstructured":"Hare, S. et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572). Mol. Pharmacol. 80, 565\u2013572, https:\/\/doi.org\/10.1124\/mol.111.073189 (2011).","journal-title":"Mol. Pharmacol."},{"key":"57843_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0040-4020(01)92175-1","volume":"14","author":"Y Hirata","year":"1961","unstructured":"Hirata, Y., Nakata, H., Yamada, K., Okuhara, K. & Naito, T. The structure of Aureothin, a nitro compound obtained from Streptomyces thioluteus. Tetrahedron 14, 252\u2013274 (1961).","journal-title":"Tetrahedron"},{"key":"57843_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/etc.5620080509","volume":"8","author":"LH Hall","year":"1989","unstructured":"Hall, L. H., Maynard, E. L. & Kier, L. B. Structure-activity relationship studies on the toxicity of benzene derivatives: III. Predictions and extension to new substituents. Environ. Toxicol. Chem. 8, 431\u2013436 (1989).","journal-title":"Environ. Toxicol. Chem."},{"key":"57843_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/ol047594l","volume":"7","author":"MF Jacobsen","year":"2005","unstructured":"Jacobsen, M. F., Moses, J. E., Adlington, R. M. & Baldwin, J. E. A short total synthesis of aureothin and N-acetylaureothamine. Org. Lett. 7, 641\u2013644, https:\/\/doi.org\/10.1021\/ol047594l (2005).","journal-title":"Org. Lett."},{"key":"57843_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.tet.2005.11.058.","volume":"62","author":"MF Jacobsen","year":"2006","unstructured":"Jacobsen, M. F., Moses, J. E., Adlington, R. M. & Baldwin, J. E. The biomimetic synthesis of SNF4435C and SNF4435D, and the total synthesis of the polyene metabolites aureothin, N-acetyl-aureothamine and spectinabilin. Tetrahedron 62, 1675\u20131689, https:\/\/doi.org\/10.1016\/j.tet.2005.11.058. (2006).","journal-title":"Tetrahedron"},{"key":"57843_CR16","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1002\/anie.200602840","volume":"45","author":"M Muller","year":"2006","unstructured":"Muller, M. et al. Photochemical origin of the immunosuppressive SNF4435C\/D and formation of orinocin through \u201cpolyene splicing\u201d. Angew. Chem. Int. Ed. Engl. 45, 7835\u20137838, https:\/\/doi.org\/10.1002\/anie.200602840 (2006).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"57843_CR17","unstructured":"Riss, T. L. et al. In Assay Guidance Manual (eds. Sittampalam, G. S. et al.) (2004)."},{"key":"57843_CR18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1097\/01.aids.0000194805.74293.11","volume":"19","author":"A Heredia","year":"2005","unstructured":"Heredia, A. et al. Indirubin-3\u2032-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19, 2087\u20132095 (2005).","journal-title":"AIDS"},{"key":"57843_CR19","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/cbic.200900303","volume":"10","author":"A Ali","year":"2009","unstructured":"Ali, A. et al. Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem 10, 2072\u20132080, https:\/\/doi.org\/10.1002\/cbic.200900303 (2009).","journal-title":"Chembiochem"},{"key":"57843_CR20","doi-asserted-by":"publisher","first-page":"a006916","DOI":"10.1101\/cshperspect.a006916","volume":"2","author":"J Karn","year":"2012","unstructured":"Karn, J. & Stoltzfus, C. M. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb. Perspect. Med. 2, a006916, https:\/\/doi.org\/10.1101\/cshperspect.a006916 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"57843_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681, https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol. Rev."},{"key":"57843_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"57843_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-6-44","volume":"6","author":"JY Feng","year":"2009","unstructured":"Feng, J. Y. et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6, 44, https:\/\/doi.org\/10.1186\/1742-4690-6-44 (2009).","journal-title":"Retrovirology"},{"key":"57843_CR24","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1073\/pnas.1210419110","volume":"110","author":"JR Pritchard","year":"2013","unstructured":"Pritchard, J. R. et al. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. USA 110, E170\u2013179, https:\/\/doi.org\/10.1073\/pnas.1210419110 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57843_CR25","doi-asserted-by":"publisher","first-page":"16498","DOI":"10.1074\/jbc.M117.791731","volume":"292","author":"KW Ahn","year":"2017","unstructured":"Ahn, K. W. & Root, M. J. Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. J. Biol. Chem. 292, 16498\u201316510, https:\/\/doi.org\/10.1074\/jbc.M117.791731 (2017).","journal-title":"J. Biol. Chem."},{"key":"57843_CR26","first-page":"137","volume":"6","author":"K Maeda","year":"1953","unstructured":"Maeda, K. Chemical studies on antibiotic substances. IV. A crystalline toxic substance of Streptomyces thioluteus producing aureothricin. J. Antibiot. 6, 137\u2013138 (1953).","journal-title":"J. Antibiot."},{"key":"57843_CR27","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1021\/acs.joc.6b00878","volume":"81","author":"M Henrot","year":"2016","unstructured":"Henrot, M., Jean, A., Peixoto, P. A., Maddaluno, J. & De Paolis, M. Flexible Total Synthesis of (+\/\u2212)-Aureothin, a Potent Antiproliferative Agent. J. Org. Chem. 81, 5190\u20135201, https:\/\/doi.org\/10.1021\/acs.joc.6b00878 (2016).","journal-title":"J. Org. Chem."},{"key":"57843_CR28","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cbic.200800301","volume":"9","author":"M Werneburg","year":"2008","unstructured":"Werneburg, M. & Hertweck, C. Chemoenzymatic total synthesis of the antiproliferative polyketide (+)-(R)-aureothin. Chembiochem 9, 2064\u20132066, https:\/\/doi.org\/10.1002\/cbic.200800301 (2008).","journal-title":"Chembiochem"},{"key":"57843_CR29","doi-asserted-by":"publisher","first-page":"10407","DOI":"10.1021\/ja102751h","volume":"132","author":"M Werneburg","year":"2010","unstructured":"Werneburg, M. et al. Exploiting enzymatic promiscuity to engineer a focused library of highly selective antifungal and antiproliferative aureothin analogues. J. Am. Chem. Soc. 132, 10407\u201310413, https:\/\/doi.org\/10.1021\/ja102751h (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"57843_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.7164\/antibiotics.53.844","volume":"53","author":"M Taniguchi","year":"2000","unstructured":"Taniguchi, M. et al. Gamma-pyrone compounds with selective and potent anti-Helicobacter pylori activity. J. Antibiot. 53, 844\u2013847, https:\/\/doi.org\/10.7164\/antibiotics.53.844 (2000).","journal-title":"J. Antibiot."},{"key":"57843_CR31","unstructured":"Bach, G., Zeeck, A., Hunsmann, G. & Jurkiewicz, E. Antivirale Substanzen und diese enthaltende Arzneimittel. German patent application DE4121468A, priority 1991."},{"key":"57843_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/acs.chemrev.5b00392","volume":"116","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y. et al. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chem. Rev. 116, 422\u2013518, https:\/\/doi.org\/10.1021\/acs.chemrev.5b00392 (2016).","journal-title":"Chem. Rev."},{"key":"57843_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","volume":"28","author":"AK Pau","year":"2014","unstructured":"Pau, A. K. & George, J. M. Antiretroviral therapy: current drugs. Infect. Dis. Clin. North. Am. 28, 371\u2013402, https:\/\/doi.org\/10.1016\/j.idc.2014.06.001 (2014).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"57843_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/HIV.S120576","volume":"9","author":"Z Dlamini","year":"2017","unstructured":"Dlamini, Z. & Hull, R. Can the HIV-1 splicing machinery be targeted for drug discovery? HIV. AIDS 9, 63\u201375, https:\/\/doi.org\/10.2147\/HIV.S120576 (2017).","journal-title":"HIV. AIDS"},{"issue":"11","key":"57843_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/v8110320","volume":"8","author":"Daniela Toro-Ascuy","year":"2016","unstructured":"Toro-Ascuy, D., Rojas-Araya, B., Valiente-Echeverria, F. & Soto-Rifo, R. Interactions between the HIV-1 Unspliced mRNA and Host mRNA Decay Machineries. Viruses, 8, https:\/\/doi.org\/10.3390\/v8110320 (2016).","journal-title":"Viruses"},{"key":"57843_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev.micro.52.1.491","volume":"52","author":"VW Pollard","year":"1998","unstructured":"Pollard, V. W. & Malim, M. H. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52, 491\u2013532, https:\/\/doi.org\/10.1146\/annurev.micro.52.1.491 (1998).","journal-title":"Annu. Rev. Microbiol."},{"issue":"1","key":"57843_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/ijms20010101","volume":"20","author":"Sylvain de Breyne","year":"2018","unstructured":"de Breyne, S. & Ohlmann, T. Focus on Translation Initiation of the HIV-1 mRNAs. Int J Mol Sci 20, https:\/\/doi.org\/10.3390\/ijms20010101 (2018).","journal-title":"International Journal of Molecular Sciences"},{"key":"57843_CR38","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.2741\/3110","volume":"13","author":"M McLaren","year":"2008","unstructured":"McLaren, M., Marsh, K. & Cochrane, A. Modulating HIV-1 RNA processing and utilization. Front. Biosci. 13, 5693\u20135707, https:\/\/doi.org\/10.2741\/3110 (2008).","journal-title":"Front. Biosci."},{"key":"57843_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1042\/BST20160113","volume":"44","author":"C Mahiet","year":"2016","unstructured":"Mahiet, C. & Swanson, C. M. Control of HIV-1 gene expression by SR proteins. Biochem. Soc. Trans. 44, 1417\u20131425, https:\/\/doi.org\/10.1042\/BST20160113 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"57843_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3851\/IMP1996","volume":"17","author":"P Borrego","year":"2012","unstructured":"Borrego, P. et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir. Ther. 17, 565\u2013570, https:\/\/doi.org\/10.3851\/IMP1996 (2012).","journal-title":"Antivir. Ther."},{"key":"57843_CR41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/00002030-199908200-00006","volume":"13","author":"M Witvrouw","year":"1999","unstructured":"Witvrouw, M. et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 13, 1477\u20131483 (1999).","journal-title":"AIDS"},{"key":"57843_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/0042-6822(91)90537-L","volume":"185","author":"K Peden","year":"1991","unstructured":"Peden, K., Emerman, M. & Montagnier, L. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185, 661\u2013672 (1991).","journal-title":"Virology"},{"key":"57843_CR43","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1128\/JVI.68.3.1581-1585.1994","volume":"68","author":"LG Gurtler","year":"1994","unstructured":"Gurtler, L. G. et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68, 1581\u20131585 (1994).","journal-title":"J. Virol."},{"key":"57843_CR44","first-page":"493","volume":"27","author":"LJM Reed","year":"1938","unstructured":"Reed, L. J. M. A Simple Method of Estimating Fifty Percent Endpoints. Am. J. Hyg. 27, 493\u2013497 (1938).","journal-title":"Am. J. Hyg."},{"key":"57843_CR45","doi-asserted-by":"publisher","unstructured":"Fuss, I. J., Kanof, M. E., Smith, P. D. & Zola, H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol Chapter 7, Unit7 1, https:\/\/doi.org\/10.1002\/0471142735.im0701s85 (2009).","DOI":"10.1002\/0471142735.im0701s85"},{"key":"57843_CR46","doi-asserted-by":"publisher","first-page":"10119","DOI":"10.1128\/JVI.77.18.10119-10124.2003","volume":"77","author":"A Brussel","year":"2003","unstructured":"Brussel, A. & Sonigo, P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77, 10119\u201310124 (2003).","journal-title":"J. Virol."},{"key":"57843_CR47","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408, https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"57843_CR48","doi-asserted-by":"publisher","unstructured":"Freudenberger, N., Meyer, T., Groitl, P., Dobner, T. & Schreiner, S. Human Adenovirus Core Protein V Is Targeted by the Host SUMOylation Machinery To Limit Essential Viral Functions. J Virol, 92, https:\/\/doi.org\/10.1128\/JVI.01451-17 (2018).","DOI":"10.1128\/JVI.01451-17"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57843-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T06:12:48Z","timestamp":1670307168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57843-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57843-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"23 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.B.-W. and M.R. are coinventors in the pending European patent application EP16720354 (US10421749 patent granted). Applicants: Helmholtz Zentrum M\u00fcnchen and Leibnitz Institut f\u00fcr Naturstoff-Forschung und Infektionsbiologie e.V. M.R. has served on the Scientific Advisory Board and as consultant of the Helmholtz Zentrum M\u00fcnchen and received consulting fees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1326"}}